Bourne Partners Announces the Acquisition of Theramed Corporation

Published Wednesday, May 14 2008

Bourne Capital Partners, LLC ("Bourne Partners") through its Canadian subsidiary, Critique Pharmaceuticals Inc., announces the acquisition of the Theramed Corporation ("Theramed").

Theramed is a full-service Canadian medical device, pharmaceutical and biotech commercialization company with warehousing, distribution, regulatory, scientific affairs and sales and marketing capability. Founded in 1994 and headquartered in the Toronto suburb of Mississauga, Ontario, Theramed focuses on providing healthcare products used in Canadian hospitals and other critical care settings.

Concurrent with the acquisition of Theramed, Bourne Partners has assigned its exclusive right to import, market and distribute COLLATAMP® G in Canada to Theramed.

COLLATAMP® G is used for local hemostasis of capillary, parenchymatous and seeping hemorrhages in areas with a high risk of infection. COLLATAMP® G contains gentamicin sulfate at a locally effective dose; systemically effective therapeutic blood or plasma levels are not generally achieved. COLLATAMP® G is approved for sale in 49 countries and received a marketing authorization from Health Canada as a Class IV medical device on August 1, 2007. COLLATAMP® G has been used in over 2 million patients and has an exemplary patient safety history.

Bourne Partners secured the exclusive Canadian distribution rights to COLLATAMP® G from EUSA Pharma (Europe) Ltd.

Banks Bourne, Senior Managing Director of Bourne Partners, remarked, "We have had extensive dealings in Canada and are excited to formally enter the Canadian pharmaceutical and medical device market. The combination of Theramed's management and infrastructure with the substantial potential of COLLATAMP® G offers dynamic growth possibilities. In addition to our current portfolio, we are aggressively pursuing business development opportunities in our areas of therapeutic focus to further Theramed's growth."

T.W. (Bill) Baugh III, Managing Director of Bourne Partners, has been named Chief Executive Officer of Theramed.

About Bourne Partners

Headquartered in Charlotte, North Carolina, Bourne Partners is a leading healthcare-focused merchant banking firm that provides financial advisory services and capital to companies throughout the world.

Advisory areas of focus include corporate partnering (joint venture/licensing), acquisition and mergers, and financing services. The firm's principals have completed over 20 transactions in the healthcare area in 17 different countries aggregating over $2.5 billion in value.

For more information on this transaction or Bourne Partners, please contact:

R. Banks Bourne, Senior Managing Director
704.552.8407 ext. 221
bbourne@bourne-partners.com

T.W. (Bill) Baugh III, Managing Director
704.552.8407 ext. 235
bbaugh@bourne-partners.com

Jeremy C. Johnson, Vice President
704.552.8407 ext. 230
jjohnson@bourne-partners.com